Optimal Stereotactic Body Radiotherapy Dosage For Hepatocellular Carcinoma
Preprint
Abstract
Background and purpose: The optimal dose and fractionation scheme of stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC) remains unclear due to different tolerated liver volumes and degrees of cirrhosis. We compared the effectiveness of stereotactic body radiation therapy dosing regimens for hepatocellular carcinoma (HCC). Methods and materials: This single-center retrospective study included 604 patients treated during 2011-2017. Biologically effective dose (BED 10 ) and equivalent dose in 2 Gym fractions (EQD 2 ) were assumed at an α/β ratio of 10. Overall survival (OS), local recurrence-free rate (LRF), intrahepatic recurrence-free rate (IRF), and progression-free survival (PFS) was evaluated in univariable and propensity-score matched analyses. Results: Median tumor size was 5.2 cm (interquartile range [IQR], 1.1-21.0). Median follow-up was 31 months in surviving patients (IQR, 3-82). High radiotherapy dose correlated with better OS, PFS, LRF and IRF. Different post-SBRT OS, PFS, LRF and IRF rates were observed for stereotactic ablative radiotherapy (SART) with BED 10 ≥100 Gy, SBRT with EQD 2 ≥74 Gy to BED 10 2 <74 Gy. Conclusions: High radiotherapy dose correlated with better outcomes. If tolerated by normal tissue, we recommend SART as a first-line ablative dose or SBRT as a second-line radical dose. Otherwise, SCRT is recommended as palliative irradiation.Keywords
All Related Versions
- Published version: Radiation Oncology, 16 (1), 1.
This publication has 25 references indexed in Scilit:
- Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)Liver Cancer, 2018
- Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular CarcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2018
- Long-Term Survival Analysis of Stereotactic Ablative Radiotherapy Versus Liver Resection for Small Hepatocellular CarcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2017
- Advances in Stereotactic Body Radiation Therapy for Hepatocellular CarcinomaSeminars in Radiation Oncology, 2017
- NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017Journal of the National Comprehensive Cancer Network, 2017
- Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular CarcinomaJournal of Clinical Oncology, 2016
- Cancer statistics in China, 2015CA: A Cancer Journal for Clinicians, 2016
- Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Prognostic Factors of Local Control, Overall Survival, and ToxicityPLOS ONE, 2013
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinomaJournal of Hepatology, 2012
- Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancerBMC Cancer, 2010